DelveInsight’s “Primary Biliary Cirrhosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Primary Biliary Cirrhosis market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Primary Biliary Cirrhosis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Primary Biliary Cirrhosis: An Overview
Primary biliary cholangitis (PBC), also called primary biliary cirrhosis, is a chronic disease in which the bile ducts in the liver are slowly destroyed. Bile is a fluid made in the liver. It aids with digestion and helps the body get rid of cholesterol, toxins, and worn-out red blood cells. When the bile ducts are damaged, bile can back up in the liver and sometimes lead to irreversible scarring of liver tissue (cirrhosis). Other possible complications of Primary Biliary Cirrhosis include an enlarged spleen, gallstones, high cholesterol levels, osteoporosis, and liver failure.
Primary Biliary Cirrhosis Market Key Facts
The serologic hallmark of Primary Biliary Cirrhosis is the anti-mitochondrial antibody (AMA), a highly disease-specific auto-antibody detected in 90–95% of Primary Biliary Cirrhosis patients.
As per the study conducted in 2016, it was reported that the point prevalence of Primary Biliary Cirrhosis was 33.8/100,000 in the Japanese population (Tanaka et al., 2019).
According to Galoosian et al. (2020), Europe and North America have the highest reported prevalence of Primary Biliary Cirrhosis worldwide.
Some of the major pharma and biotech giants, such as Genfit, CymaBay Therapeutics, Calliditas Therapeutics, Zydus-Cadila, Chia Tai Tianqing Pharmaceutical Group, Cour Pharmaceutical Development, Ascletis, Novartis, Mirum Pharmaceuticals, Intercept Pharmaceuticals, HighTide Biopharma, PRISM Pharma Co, GlaxoSmithKline, and others are actively working in the Primary Biliary Cirrhosis therapeutics market.
The potential emerging therapies, such as Elafibranor, Saroglitazar Mg, CR845, Seladelpar, Seladelpar, HTD 1801, GKT137831, and CR845, and others, are anticipated to change the Primary Biliary Cirrhosis treatment scenario in the coming years.
Increased awareness of this unique histology has allowed for the development of drugs that are specific to Primary Biliary Cirrhosis and has begun to shed light on the similarities and possible unique aspects.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Primary Biliary Cirrhosis market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Primary Biliary Cirrhosis market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Primary Biliary Cirrhosis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
The Report Covers the Primary Biliary Cirrhosis Epidemiology Segmented by-
Total Prevalent Cases of Primary Biliary Cirrhosis
Diagnosed and Treatable Cases of Primary Biliary Cirrhosis
Age-specific Prevalent Cases of Primary Biliary Cirrhosis
Gender-specific Prevalent Cases of Primary Biliary Cirrhosis
Primary Biliary Cirrhosis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Primary Biliary Cirrhosis market or expected to get launched during the study period. The analysis covers the Primary Biliary Cirrhosis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Primary Biliary Cirrhosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Primary Biliary Cirrhosis Market Will Evolve by 2032:
Some of the key Companies in the Primary Biliary Cirrhosis Therapeutics Market Include:
Chia Tai Tianqing Pharmaceutical Group
Cour Pharmaceutical Development
PRISM Pharma Co
And many others
Primary Biliary Cirrhosis Therapies Covered in the Report Include:
Seladelpar: CymaBay Therapeutics
Setanaxib: Calliditas Therapeutics
HTD 1801: HighTide
CR845: Cara Therapeutics
Saroglitazar Mg: ZydusCadila
And many others
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More:
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Primary Biliary Cirrhosis Competitive Intelligence Analysis
4. Primary Biliary Cirrhosis Market Overview at a Glance
5. Primary Biliary Cirrhosis Disease Background and Overview
6. Primary Biliary Cirrhosis Patient Journey
7. Primary Biliary Cirrhosis Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Primary Biliary Cirrhosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Primary Biliary Cirrhosis Unmet Needs
10. Key Endpoints of Primary Biliary Cirrhosis Treatment
11. Primary Biliary Cirrhosis Marketed Products
12. Primary Biliary Cirrhosis Emerging Drugs and Latest Therapeutic Advances
13. Primary Biliary Cirrhosis Seven Major Market Analysis
14. Attribute Analysis
15. Primary Biliary Cirrhosis Market Outlook (In US, EU5, and Japan)
16. Primary Biliary Cirrhosis Access and Reimbursement Overview
17. KOL Views on the Primary Biliary Cirrhosis Market
18. Primary Biliary Cirrhosis Market Drivers
19. Primary Biliary Cirrhosis Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report:
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States